 look at distribution at the cellular level. In aim 2, class II peptdes, which stimulate helper T cells, will be incorporated in the AuNV design. In vivo enhancement of antitumor efficacies will be assessed with known class II peptides. However for unknown class II peptides situations, peptide pools will be used to incorporate both
look at distribution at the cellular level. In aim 2, class II peptdes, which provoke assistant T cells, will be incorporated in the AuNV purpose. In vivo enhancement of antitumor efficacies will be assessed with know class II peptides. However for nameless class II peptides site, peptide pools will be used to integrate both
 lolk at distribution at tht cellular level. Nb aim 2, class II peptaes, which stimulate helper T cwlls, qill be incorporated iv the AuNN design. Un vmvo enhancement of antitmior snficaeixs will be assexsed with nnown class II pdpcides. However for unknown class II pqptides sltuations, peptyde koojs wjll be used to incorporate both
look at distribution at the cellular level. 2, II peptdes, stimulate helper T the design. In vivo of antitumor efficacies be assessed with known class II However for unknown class II peptides situations, peptide pools will be used to both
 look at distribution at the ceLlular leveL. In aiM 2, clAss iI PeptDes, wHich stimulate hELper t cells, will be incorporatEd in tHe aUNV dESiGn. In vIvo enhaNCeMENt oF aNtItuMoR EfFicacIes Will be aSsessed witH knOwN class II peptIDeS. However foR unKnown class II PepTides sItUatIOns, pePtiDe pooLs will BE used tO incorporAtE Both
 look at distribution at t he cellula r lev el.  In  a im 2 , cl ass II peptdes ,  whi ch stimulate helper Tcells ,w illb eincor porated in t heAu NV  de si g n.  In v ivo  enhanc ement of a nti tu mor efficaci e swill be as ses sed with kno wnclassII  pe p tides . H oweve r foru nknown  class II  p e ptides situati o n s,  pep tide pools will b e  u s ed to incorpor ate bo th 
 look_at distribution_at the cellular level._In aim_2,_class II_peptdes,_which stimulate helper_T cells, will_be incorporated in the_AuNV design. In_vivo_enhancement of antitumor efficacies will be assessed with known class II peptides. However for_unknown_class II_peptides_situations,_peptide pools will be used_to incorporate both